Immuneering Co. (NASDAQ:IMRX) Receives Average Rating of “Hold” from Analysts

Immuneering Co. (NASDAQ:IMRX) has been given a consensus rating of “Hold” by the eight analysts that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $12.80.

IMRX has been the topic of a number of recent analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $15.00 price target on shares of Immuneering in a research report on Tuesday. Morgan Stanley downgraded shares of Immuneering from an “equal weight” rating to an “underweight” rating in a report on Friday, December 13th. Finally, Chardan Capital restated a “buy” rating and set a $13.00 price target on shares of Immuneering in a report on Wednesday.

Immuneering Stock Performance

Shares of IMRX stock opened at $2.00 on Thursday. The stock’s 50 day simple moving average is $2.04 and its 200 day simple moving average is $1.77. Immuneering has a twelve month low of $1.00 and a twelve month high of $7.68. The company has a market capitalization of $62.10 million, a price-to-earnings ratio of -1.02 and a beta of -0.34.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Acadian Asset Management LLC bought a new position in shares of Immuneering during the 2nd quarter worth about $67,000. Renaissance Technologies LLC bought a new position in Immuneering during the second quarter worth about $447,000. XTX Topco Ltd boosted its holdings in Immuneering by 37.3% during the second quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock valued at $44,000 after purchasing an additional 9,274 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Immuneering in the 2nd quarter valued at approximately $492,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Immuneering in the 2nd quarter worth approximately $44,000. 67.65% of the stock is owned by institutional investors.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.